Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 13.53% | Reduce −19.7% | 4,423,369 | $27.13 | $120M | −1,088,352 | −$51M |
| FOLD - Amicus | 12.41% | Reduce −9.9% | 9,344,102 | $11.78 | $110M | −1,029,613 | −$37M |
| BMRN - Biomarin Pharmaceutical | 11.18% | Reduce −24.4% | 1,134,569 | $87.34 | $99M | −366,180 | −$46M |
| BIIB - Biogen | 7.05% | Reduce −23.8% | 289,958 | $215.63 | $63M | −90,459 | −$36M |
| UTHR - United Therapeutics | 6.94% | Reduce −32.3% | 267,759 | $229.72 | $62M | −128,025 | −$26M |
| Staar Surgical | 5.96% | Add +0.2% | 1,379,590 | $38.28 | $53M | +2,640 | +$10M |
| ACAD - Acadia Pharmaceuticals | 5.04% | Add +0.2% | 2,414,943 | $18.49 | $45M | +5,387 | −$31M |
| PRTA - Prothena | 4.65% | Add +0.2% | 1,663,448 | $24.77 | $41M | +3,391 | −$19M |
| IOVA - Iovance Biotherapeutics | 3.53% | Add +0.3% | 2,112,811 | $14.82 | $31M | +6,019 | +$14M |
| ALNY - Alnylam Pharmaceuticals | 3.08% | Add +18.3% | 182,766 | $149.45 | $27M | +28,329 | −$2M |
| Sarepta Therapeutics | 2.94% | Add +0.2% | 201,265 | $129.46 | $26M | +360 | +$7M |
| Revance Therapeutics | 2.91% | Add +0.2% | 5,248,004 | $4.92 | $26M | +10,720 | −$20M |
| Sage Therapeutics | 2.13% | Add +1.4% | 1,005,776 | $18.74 | $19M | +14,251 | −$3M |
| ANAB - Anaptysbio | 2.03% | Add +16.5% | 799,906 | $22.52 | $18M | +113,024 | +$3M |
| EHTH - Ehealth | 1.85% | Reduce −0.9% | 2,715,681 | $6.03 | $16M | −23,698 | −$8M |
| ALGN - Align Technology | 1.82% | Reduce −11.8% | 49,105 | $327.92 | $16M | −6,600 | +$839K |
| ALKS - Alkermes | 1.51% | Reduce −17.9% | 495,592 | $27.07 | $13M | −107,808 | −$3M |
| Acelyrin | 1.31% | New | 1,715,180 | $6.75 | $12M | +1,715,180 | +$12M |
| Nevro | 1.22% | Hold | 750,371 | $14.44 | $11M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.09% | Reduce −14.3% | 405,193 | $23.80 | $10M | −67,407 | −$569K |
| NVCR - Novocure | 0.99% | Hold | 561,908 | $15.63 | $9M | — | — |
| CYTK - Cytokinetics | 0.88% | Hold | 111,717 | $70.11 | $8M | — | — |
| Karyopharm Therapeutics | 0.87% | Hold | 5,102,193 | $1.51 | $8M | — | — |
| Verve Therapeutics | 0.86% | Hold | 575,817 | $13.28 | $8M | — | — |
| Gossamer Bio | 0.85% | Add +84.5% | 6,391,775 | $1.18 | $8M | +2,926,623 | +$4M |
| Elevation Oncology | 0.78% | New | 1,346,666 | $5.13 | $7M | +1,346,666 | +$7M |
| Bluebird Bio | 0.66% | Add +36.8% | 4,560,171 | $1.28 | $6M | +1,226,838 | +$1M |
| RLMD - Relmada Therapeutics | 0.38% | Hold | 732,400 | $4.65 | $3M | — | — |
| NUVB - Nuvation Bio | 0.32% | New | 772,652 | $3.64 | $3M | +772,652 | +$3M |
| TSHA - Taysha Gene Therapies | 0.26% | Add +53.1% | 811,268 | $2.87 | $2M | +281,407 | +$1M |
| STOK - Stoke Therapeutics | 0.19% | New | 125,861 | $13.50 | $2M | +125,861 | +$2M |
| MIRM - Mirum Pharmaceuticals | 0.18% | Hold | 64,700 | $25.12 | $2M | — | — |
| HUM - Humana | 0.16% | New | 3,985 | $346.72 | $1M | +3,985 | +$1M |
| Vyne Therapeutics | 0.15% | Hold | 445,434 | $3.07 | $1M | — | — |
| TVTX - Travere Therapeutics | 0.10% | Hold | 110,719 | $7.71 | $854K | — | — |
| ALDX - Aldeyra Therapeutics | 0.08% | Hold | 225,465 | $3.27 | $737K | — | — |
| ACRS - Aclaris Therapeutics | 0.08% | New | 569,832 | $1.24 | $707K | +569,832 | +$707K |
| URGN - Urogen Pharma | 0.04% | Hold | 24,500 | $15.00 | $368K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| VNDA - Vanda Pharmaceuticals | 0.11% | Exit | 0 | $4.22 | $1M | −278,985 | −$1M |
| Sight Sciences | 0.08% | Exit | 0 | $5.16 | $897K | −173,790 | −$897K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2